Ra Capital Management as of June 30, 2015
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 58 positions in its portfolio as reported in the June 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Axovant Sciences | 10.2 | $102M | 5.0M | 20.38 | |
| Achillion Pharmaceuticals | 8.9 | $88M | 9.9M | 8.86 | |
| Sangamo Biosciences (SGMO) | 8.1 | $80M | 7.2M | 11.09 | |
| Dyax | 7.2 | $72M | 2.7M | 26.50 | |
| Tg Therapeutics (TGTX) | 5.5 | $55M | 3.3M | 16.59 | |
| Regulus Therapeutics | 4.2 | $42M | 3.8M | 10.96 | |
| Coherus Biosciences (CHRS) | 4.0 | $40M | 1.4M | 28.90 | |
| BioCryst Pharmaceuticals (BCRX) | 3.9 | $39M | 2.6M | 14.93 | |
| Dicerna Pharmaceuticals | 3.4 | $34M | 2.4M | 13.95 | |
| Ascendis Pharma A S (ASND) | 3.4 | $34M | 1.9M | 17.68 | |
| Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 2.8 | $28M | 1.5M | 17.84 | |
| Ardelyx (ARDX) | 2.8 | $28M | 1.7M | 15.97 | |
| Proteon Therapeutics | 2.7 | $27M | 1.5M | 17.86 | |
| Xencor (XNCR) | 2.4 | $24M | 1.1M | 21.97 | |
| Blueprint Medicines (BPMC) | 2.3 | $23M | 878k | 26.49 | |
| Bellicum Pharma | 2.2 | $22M | 1.0M | 21.27 | |
| Medicines Company | 2.0 | $20M | 706k | 28.61 | |
| Bluebird Bio (BLUE) | 1.9 | $18M | 109k | 168.37 | |
| Dynavax Technologies (DVAX) | 1.8 | $18M | 766k | 23.43 | |
| Cidara Therapeutics Inc Common Stock Usd 0.0001 | 1.6 | $16M | 1.1M | 14.02 | |
| Novavax | 1.6 | $16M | 1.4M | 11.14 | |
| Juno Therapeutics | 1.5 | $15M | 280k | 53.33 | |
| Agenus | 1.4 | $14M | 1.6M | 8.63 | |
| Omeros Corporation (OMER) | 1.4 | $14M | 749k | 17.99 | |
| Therapeuticsmd | 1.3 | $13M | 1.7M | 7.86 | |
| Agile Therapeutics | 1.3 | $13M | 1.5M | 8.59 | |
| Nivalis Therapeutics | 1.1 | $12M | 757k | 15.15 | |
| Seres Therapeutics (MCRB) | 1.0 | $10M | 247k | 41.50 | |
| Alcobra | 1.0 | $10M | 1.5M | 6.54 | |
| Concert Pharmaceuticals I equity | 1.0 | $10M | 668k | 14.89 | |
| Tenax Therapeutics | 1.0 | $9.9M | 2.7M | 3.69 | |
| Sucampo Pharmaceuticals | 0.7 | $7.4M | 450k | 16.43 | |
| Arca Biopharma | 0.7 | $6.5M | 5.7M | 1.15 | |
| Auris Med Hldg | 0.5 | $4.6M | 940k | 4.86 | |
| Aurinia Pharmaceuticals (AUPH) | 0.3 | $3.5M | 1.1M | 3.02 | |
| Trevena | 0.3 | $3.3M | 528k | 6.26 | |
| T2 Biosystems | 0.2 | $2.2M | 138k | 16.23 | |
| Vical Incorporated | 0.2 | $1.8M | 2.6M | 0.70 | |
| Biota Pharmaceuticals | 0.2 | $1.7M | 808k | 2.07 | |
| Merrimack Pharmaceuticals In | 0.1 | $1.4M | 116k | 12.36 | |
| Tesaro | 0.1 | $1.4M | 24k | 58.81 | |
| Regeneron Pharmaceuticals (REGN) | 0.1 | $1.2M | 2.5k | 510.20 | |
| Newlink Genetics Corporation | 0.1 | $1.3M | 30k | 44.27 | |
| Neurocrine Biosciences (NBIX) | 0.1 | $1.2M | 24k | 47.75 | |
| Alkermes (ALKS) | 0.1 | $1.2M | 19k | 64.32 | |
| Clovis Oncology | 0.1 | $1.2M | 13k | 87.88 | |
| Ptc Therapeutics I (PTCT) | 0.1 | $1.2M | 26k | 48.14 | |
| Incyte Corporation (INCY) | 0.1 | $1.1M | 11k | 104.21 | |
| Biogen Idec (BIIB) | 0.1 | $1.1M | 2.6k | 403.85 | |
| ACADIA Pharmaceuticals (ACAD) | 0.1 | $1.1M | 27k | 41.87 | |
| Agios Pharmaceuticals (AGIO) | 0.1 | $1.1M | 9.9k | 111.11 | |
| Celgene Corporation | 0.1 | $1.0M | 8.7k | 115.75 | |
| Amgen (AMGN) | 0.1 | $906k | 5.9k | 153.56 | |
| Array BioPharma | 0.1 | $909k | 126k | 7.21 | |
| DURECT Corporation | 0.1 | $913k | 382k | 2.39 | |
| Wafergen Bio-systems | 0.1 | $647k | 205k | 3.15 | |
| Keryx Biopharmaceuticals | 0.1 | $591k | 59k | 9.98 | |
| Puma Biotechnology (PBYI) | 0.0 | $362k | 3.1k | 116.77 |
